FDA approves prostate cancer imaging technique developed by Pharmacology faculty
![Calais+Czernin](/sites/g/files/oketem666/files/styles/3_2_480x320/public/media/images/Calais%2BCzernin%2BTW_mid.jpg.webp?itok=zq5pvPy4)
The FDA recently granted a New Drug Application (NDA) for a novel prostate cancer imaging approach (PSMA-PET) to UCLA and UCSF, the outcome of a four-year interdepartmental and inter-institutional collaboration. The UCLA cohort was directed by Drs. Johannes Czernin and Jeremie Calais.